Effectiveness of pembrolizumab in trial-ineligible patients with metastatic urothelial carcinoma.

Wataru FukuokayaTakafumi YanagisawaMasaki HashimotoShutaro YamamotoYuhei KoikeYu ImaiKosuke IwataniHajime OnumaKagenori ItoFumihiko UrabeShunsuke TsuzukiShoji KimuraJun MikiYu OyamaHirokazu AbeTakahiro Kimura

Published in: Cancer immunology, immunotherapy : CII (2022)

This study suggests that the effectiveness of pembrolizumab may be retained in ineligible patients with platinum-treated metastatic UC. Expanding trial eligibility criteria for these patients may be beneficial.

Keyphrases

randomized controlled trial
end stage renal disease
study protocol
newly diagnosed
systematic review
phase iii
clinical trial
ejection fraction
phase ii
advanced non small cell lung cancer
chronic kidney disease
prognostic factors
peritoneal dialysis
patient reported outcomes